logo
Select company
Select metric
$ -306.64MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
3
Sector
5
Industry
6
History
61
$ 6.49Close
$ 2 - $ 6.78 52-Week Range
Ticker Information

Ticker

RLAY

Company Name

RELAY THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

RELAY THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

RLAY - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 4.91M$ -311.55M$ -306.64M
3/31/2025$ 5.28M$ -333.39M$ -328.11M
12/31/2024$ 5.46M$ -337.71M$ -332.24M
9/30/2024$ 5.5M$ -345.2M$ -339.69M
6/30/2024$ 5.5M$ -322.83M$ -317.33M
3/31/2024$ 5.47M$ -329.12M$ -323.65M
12/31/2023$ 5.27M$ -341.97M$ -336.7M
9/30/2023$ 5.06M$ -325.98M$ -320.92M
6/30/2023$ 4.73M$ -344.42M$ -339.69M
3/31/2023$ 4.35M$ -322.7M$ -318.35M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • RELAY THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -48.86M.
  • Over the past 5 years, RELAY THERAPEUTICS INC's average EBITDA has been $ -286.53M.
  • The median EBITDA for RELAY THERAPEUTICS INC during this period was $ -318.35M
  • RELAY THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -48.86M.
  • The lowest EBITDA recorded by RELAY THERAPEUTICS INC in the same timeframe $ -379.75M

RELAY THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
TSHA : TAYSHA GENE THERAPIES INC $ -90.23MDNTH : DIANTHUS THERAPEUTICS INC $ -114.33MTNXP : TONIX PHARMACEUTICALS HOLDING CORP $ -79.44MPRME : PRIME MEDICINE INC $ -183.24MPGEN : PRECIGEN INC $ -121.97MPRTA : PROTHENA CORP PUBLIC LTD CO $ -258.05MABSI : ABSCI CORP $ -100.08MFATE : FATE THERAPEUTICS INC $ -155.49MTVRD : TVARDI THERAPEUTICS INC $ -13.45MPRAX : PRAXIS PRECISION MEDICINES INC $ -249.79M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for RELAY THERAPEUTICS INC is calculated as follows: EBIT [ $ -52.41M ] + DepAmor [ $ 3.55M ]
(=) EBITDA [ $ -48.86M ]

RLAY - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -379.75M

Minimum

Mar 31, 2022

$ -48.86M

Maximum

Dec 31, 2020

$ -286.53M

Average

$ -318.35M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M